The unprecedented health crisis caused by the coronavirus disease 2019 (COVID-19) pandemic has affected over 247 million individuals to date. Monoclonal antibodies (mAbs) that target the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein have been found to have good neutralization efficacy in the treatment of Ebola virus, SARS, middle east respiratory syndrome (MERS), […]
Home »
Study of SARS-CoV-2 antibody seroprevalence among domestic cats
The idea that coronavirus disease 2019 (COVID-19) is a zoonotic disease is very popular. The theory that the initial case occurred from transmission from a bat in a wet market in Wuhan gained massive media attention in the first months of the pandemic. While other theories have gained more attention since there can be no […]
Monoclonal antibody treatment combo reduces hospitalization among high-risk patients with COVID-19
In an observational study, Mayo Clinic researchers report that the combination of casirivimab and imdevimab—two monoclonal antibody treatments under Food and Drug Administration emergency use authorization—keep high-risk patients out of the hospital when infected with mild to moderate COVID-19. The findings appear in The Lancet’s EClinicalMedicine. Nearly 1,400 Mayo Clinic patients were enrolled in the […]
COVID-19 antibody ‘cocktail’ protects chronically ill: study
A monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca reduced the risk of symptoms in a study of immunocompromised and chronically ill adults later exposed to the virus by 77%, the company announced today. Based on the positive results from the PROVENT Phase III trial, the […]
Antibody combo prevents infection from SARS-CoV-2 exposure
(HealthDay)—For household contacts of infected persons, subcutaneous REGEN-COV, a combination of the monoclonal antibodies casirivimab and imdevimab, prevents symptomatic and asymptomatic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, according to a study published online Aug. 4 in the New England Journal of Medicine. Meagan P. O’Brien, M.D., from Regeneron Pharmaceuticals in Tarrytown, New York, […]
COVID-19 vaccination induces highly variable immunity among the immunocompromised
Researchers in the United States have conducted a study showing that the humoral (antibody) immunity induced by vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – varies significantly among immunocompromised individuals. The findings come from an interim analysis of an ongoing observational, prospective cohort analysis […]
FairJourney Biologics introduces “THE ANTIBODY SERIES” conference
FairJourney Biologics S.A. (FJB), leaders in the discovery and optimization of antibodies, today announced the launch of the “THE ANTIBODY SERIES” – a 1-day conference bringing together top experts in the antibody field to explore the latest innovation within antibody drug discovery. The conference is being launched in Porto, Portugal, celebrating FairJourney Biologics’ inauguration of […]
Oxford study sheds light on level of antibodies needed to protect against COVID-19 symptoms
Researchers in the UK have reported on the relationship between humoral (antibody) responses and protection against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) following immunization with AstraZeneca’s ChAdOx1 vaccine. The SARS-CoV-2 virus is the agent responsible for the coronavirus disease 2019 (COVID-19) pandemic that continues to pose a threat to global public health […]
What is the role of monoclonal antibody therapy in treating COVID-19?
The causal agent of the coronavirus disease 2019 (COVID-19) is severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which belongs to the genus Betacoronavirus of the Coronaviridae family. Other coronaviruses that caused epidemics are SARS-CoV and MERS-CoV. SARS-CoV-2 is a positive-sense RNA genome, is extremely infectious, and has claimed more than 3.7 million lives worldwide. The transmission […]
Pfizer/BioNTech COVID-19 vaccine induces a stronger antibody response when given at an extended interval
Scientists from the University of Birmingham and the Public Health England, UK, have recently investigated the dynamics of immune responses in elderly people who have received two doses of the Pfizer/BioNTech coronavirus disease 2019 (COVID-19) vaccine at a standard or extended interval. The study findings reveal that an extended interval vaccination can enhance the humoral […]